Key patents for gene-editing technology are at stake.
The legal war for CRISPR gene-editing technology is heating up, with several biotechs joining forces to coordinate the defense and enforcement of key patents. An invention management deal has been struck by CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics covering the CRISPR/Cas9-related intellectual property owned by the University of California, Emmanuelle Charpentier and University of Vienna, according to Scientific American.
The Broad Institute and Editas Medicine, which draws its IP from the Broad, disagrees. While the University of California's Jennifer Doudna published the landmark 2012 study showing CRISPR's gene-editing potential, The Broad believes its researcher Feng Zheng made the crucial scientific step which demonstrated CRISPR could be applied to human DNA. Under now-changed patent rules, The Board was awarded the initial patent.
UC is challenging that decision by the U.S. Patent Office through a process known as "interference." The first and only oral arguments in the case were held earlier this month and a decision is likely sometime next year.
"Intellia, CRISPR Therapeutics, Caribou and ERS view this agreement as enhancing the efforts to protect our shared intellectual property rights and support the ongoing development of our product candidates, as well as those of our corresponding partners and licensees," Novak said.
Per the deal, each of the co-owners (i.e. UC, Charpentier or the University of Vienna) grants so-called cross-consents to "all existing and future licenses based on the rights of another co-owner." The agreement unites the biotechs aligned with UC into a more cohesive group opposing the Broad and Editas. Yet even if the Broad wins, the impact to the biotechs themselves may less damaging than first appearances.
A verdict would probably force the biotechs on one side or the other to negotiate new licenses from the winning party, according to MIT Technology Review. That would cost money and could entail royalties for any future products that make it to market. Biotechs on each side should be able to continue their march towards human testing of CRISPR.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.